Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rabies virus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Rabies virus. Displaying page 1 of 1.
    EudraCT Number: 2021-005564-21 Sponsor Protocol Number: SIRAVA Start Date*: 2021-12-28
    Sponsor Name:Leiden University Medical Center
    Full Title: Five-year boostability after single-visit single-dose intramuscular rabies pre-exposure prophylaxis.
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10069589 Rabies immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000089-31 Sponsor Protocol Number: PREPARE Start Date*: 2017-08-09
    Sponsor Name:Leiden University Medical Center
    Full Title: Single dose rabies PRE-exposure Priming induces a rapid and effective anamnestic Antibody REsponse
    Medical condition: healthy volunteer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10069589 Rabies immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005173-23 Sponsor Protocol Number: V49_23 Start Date*: 2012-03-08
    Sponsor Name:Novartis Vaccines and Diagnostics GmbH
    Full Title: A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Differ...
    Medical condition: Safety and Immunogenicity of Rabies Vaccine and Japanese Encephalitis Vaccine administered concomitantly and/or separately according to 1 of 2 different pre-exposure prophylaxis schedules to health...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10037742 Rabies PT
    14.1 10021881 - Infections and infestations 10023123 Japanese encephalitis LLT
    14.1 10021881 - Infections and infestations 10037743 Rabies viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004008-36 Sponsor Protocol Number: VRV09 Start Date*: 2020-09-07
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Purified Vero Rabies Vaccine– Serum Free (VRVg) Assessed with the Institut Pasteur du Cambodge (IPC: 2-2-2-0-0) and the Thai Red Cross (TRC: 2-2-2-0-2) Intradermal Re...
    Medical condition: Rabies (Healthy Volunteers)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037742 Rabies PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000382-31 Sponsor Protocol Number: 205214 Start Date*: 2015-07-28
    Sponsor Name:GlaxoSmithKline Biologicals S.A.
    Full Title: A Phase III, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults who Received Different Primary Vaccination Regimens of Pre-exposure Pr...
    Medical condition: Rabies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037742 Rabies PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002367-29 Sponsor Protocol Number: ITM202203 Start Date*: 2022-09-29
    Sponsor Name:Instituut van Tropische Geneeskunde Antwerpen
    Full Title: A two-centre open-label non-inferiority trial to assess the immunogenicity and safety of an intradermal and an intramuscular single-visit dosing regimen of purified chick-embryo cell-culture rabies...
    Medical condition: Rabies is a viral infection that affects the central nervous system. It causes encephalitis which is almost invariably fatal. Preventive vaccination alone implies no complete protection, but simpli...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037742 Rabies PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001223-14 Sponsor Protocol Number: VAJ00001 Start Date*: 2020-11-13
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Imovax® Rabies and VERORAB® Immunogenicity and Safety after One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscu...
    Medical condition: Rabies disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10069573 Rabies immunisation PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002096-34 Sponsor Protocol Number: AER-2012 Start Date*: 2012-10-29
    Sponsor Name:Crucell Holland B.V.
    Full Title: Research towards presence of Antibodies against European Bat Lyssavirus (EBLV) after immunization with Rabipur®
    Medical condition: healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10069589 Rabies immunization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000973-22 Sponsor Protocol Number: VRV12 Start Date*: 2020-11-15
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free in Comparison with Verorab® and Imovax® Rabies, in a Pre-exposure Regimen in Both Pediatric and Adult Populations and a Sing...
    Medical condition: Rabies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037742 Rabies PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004055-20 Sponsor Protocol Number: VRV13 Start Date*: 2019-05-14
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free in Comparison with Verorab® and Imovax® Rabies, in a Simulated Rabies Post-exposure Regimen in Healthy Adults in France
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037742 Rabies PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001836-12 Sponsor Protocol Number: ITMC0414 Start Date*: 2014-07-31
    Sponsor Name:Institute of Tropical Medicine
    Full Title: Boostability for rabies in last-minute travelers: One Day Rabies Pre-exposure Intradermal Vaccination followed by one day Postexposure Intradermal Vaccination
    Medical condition: Rabies is a viral infection that affects the central nervous system. It causes encephalitis which is almost invariably fatal. Preventive vaccination alone implies no complete protection, but simpli...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001612-62 Sponsor Protocol Number: ITMC0211 Start Date*: 2011-09-06
    Sponsor Name:Institute of Tropical Medicine Antwerp
    Full Title: Simplifying the Rabies Pre-exposure Vaccination
    Medical condition: Rabies is a viral infection that affects the central nervous system. It causes encephalitis which is almost invariably fatal. Preventive vaccination alone implies no complete protection, but simpli...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009877-85 Sponsor Protocol Number: VRV01 Start Date*: 2009-06-23
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity of the Purified Vero Rabies Vaccine – Serum Free in Comparison with the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults
    Medical condition: Prophylactic Immunization against Rabies
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004707-40 Sponsor Protocol Number: RAB40 Start Date*: 2019-02-25
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Verorab® immunogenicity and safety after a one week, 4-site, intradermal (ID) post-exposure prophylaxis regimen (4-4-4-0-0) followed by a one visit, 4-site, ID booster at five years.
    Medical condition: Rabies
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003203-30 Sponsor Protocol Number: VRV06 Start Date*: 2016-04-15
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Purified Vero Rabies Vaccine- Serum Free (VRVg) in Comparison with the Human Diploid Cell Vaccine, IMOVAX® Rabies in a Pre-exposure Prophylaxis Regimen in Healthy C...
    Medical condition: Rabies infection
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005194-20 Sponsor Protocol Number: VRV08 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison with the Reference Purified Vero Rabies Vaccine in Post-exposure Use in Healthy Subjects in China
    Medical condition: Prophylactic Immunization against Rabies
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000475-14 Sponsor Protocol Number: V59_38 Start Date*: 2011-10-25
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in He...
    Medical condition: Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-000290-20 Sponsor Protocol Number: 204889 Start Date*: 2017-09-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Phase IIb randomized, open-label, controlled, multi-center study of the efficacy, safety and immunogenicity of GSK Biologicals’ candidate malaria vaccine RTS,S/AS01E evaluating schedules with or wi...
    Medical condition: Healthy volunteers (primary immunization against malaria disease caused by Plasmodium falciparum)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10025487 Malaria PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005716-26 Sponsor Protocol Number: 110021 Start Date*: 2015-06-17
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, double blind (observer-blind), randomized, controlled multi-center study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease...
    Medical condition: Healthy volunteers (Primary and booster immunization against Plasmodium falciparum malaria)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 01:05:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA